These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 21764342)

  • 21. Transient protein states in designing inhibitors of the MDM2-p53 interaction.
    Bista M; Wolf S; Khoury K; Kowalska K; Huang Y; Wrona E; Arciniega M; Popowicz GM; Holak TA; Dömling A
    Structure; 2013 Dec; 21(12):2143-51. PubMed ID: 24207125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Computational studies and peptidomimetic design for the human p53-MDM2 complex.
    Zhong H; Carlson HA
    Proteins; 2005 Jan; 58(1):222-34. PubMed ID: 15505803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Probing Difference in Binding Modes of Inhibitors to MDMX by Molecular Dynamics Simulations and Different Free Energy Methods.
    Shi S; Zhang S; Zhang Q
    PLoS One; 2015; 10(10):e0141409. PubMed ID: 26513747
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Microsecond simulations of mdm2 and its complex with p53 yield insight into force field accuracy and conformational dynamics.
    Pantelopulos GA; Mukherjee S; Voelz VA
    Proteins; 2015 Sep; 83(9):1665-76. PubMed ID: 26138282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Calculation of hot spots for protein-protein interaction in p53/PMI-MDM2/MDMX complexes.
    Huang D; Qi Y; Song J; Zhang JZH
    J Comput Chem; 2019 Apr; 40(9):1045-1056. PubMed ID: 30549062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thermodynamic and computational studies on the binding of p53-derived peptides and peptidomimetic inhibitors to HDM2.
    Grässlin A; Amoreira C; Baldridge KK; Robinson JA
    Chembiochem; 2009 May; 10(8):1360-8. PubMed ID: 19408261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Crystallographic analysis of an 8-mer p53 peptide analogue complexed with MDM2.
    Sakurai K; Schubert C; Kahne D
    J Am Chem Soc; 2006 Aug; 128(34):11000-1. PubMed ID: 16925398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structure of the stapled p53 peptide bound to Mdm2.
    Baek S; Kutchukian PS; Verdine GL; Huber R; Holak TA; Lee KW; Popowicz GM
    J Am Chem Soc; 2012 Jan; 134(1):103-6. PubMed ID: 22148351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative lid dynamics of MDM2 reveals differential ligand binding modes of the p53-binding cleft.
    Showalter SA; Bruschweiler-Li L; Johnson E; Zhang F; Brüschweiler R
    J Am Chem Soc; 2008 May; 130(20):6472-8. PubMed ID: 18435534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kinetic and thermodynamic effects of phosphorylation on p53 binding to MDM2.
    Yadahalli S; Neira JL; Johnson CM; Tan YS; Rowling PJE; Chattopadhyay A; Verma CS; Itzhaki LS
    Sci Rep; 2019 Jan; 9(1):693. PubMed ID: 30679555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Screening of medicinal plant phytochemicals as natural antagonists of p53-MDM2 interaction to reactivate p53 functioning.
    Riaz M; Ashfaq UA; Qasim M; Yasmeen E; Ul Qamar MT; Anwar F
    Anticancer Drugs; 2017 Oct; 28(9):1032-1038. PubMed ID: 28723868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protein-peptide molecular docking with large-scale conformational changes: the p53-MDM2 interaction.
    Ciemny MP; Debinski A; Paczkowska M; Kolinski A; Kurcinski M; Kmiecik S
    Sci Rep; 2016 Dec; 6():37532. PubMed ID: 27905468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploring the binding mechanisms of MIF to CXCR2 using theoretical approaches.
    Xu L; Li Y; Li D; Xu P; Tian S; Sun H; Liu H; Hou T
    Phys Chem Chem Phys; 2015 Feb; 17(5):3370-82. PubMed ID: 25526079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Helix stabilized, thermostable, and protease-resistant self-assembled peptide nanostructures as potential inhibitors of protein-protein interactions.
    Jeong WJ; Lee MS; Lim YB
    Biomacromolecules; 2013 Aug; 14(8):2684-9. PubMed ID: 23844716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simulation of MDM2 N-terminal domain conformational lability in the presence of imidazoline based inhibitors of MDM2-p53 protein-protein interaction.
    Gureev M; Novikova D; Grigoreva T; Vorona S; Garabadzhiu A; Tribulovich V
    J Comput Aided Mol Des; 2020 Jan; 34(1):55-70. PubMed ID: 31781989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.
    Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT
    Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular interaction fields and 3D-QSAR studies of p53-MDM2 inhibitors suggest additional features of ligand-target interaction.
    Dezi C; Carotti A; Magnani M; Baroni M; Padova A; Cruciani G; Macchiarulo A; Pellicciari R
    J Chem Inf Model; 2010 Aug; 50(8):1451-65. PubMed ID: 20726601
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Binding Ensembles of
    Lang L; Perez A
    Molecules; 2021 Jan; 26(1):. PubMed ID: 33401765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Study of MDM2 binding to p53-analogues: affinity, helicity, and applicability to drug design.
    Kalid O; Ben-Tal N
    J Chem Inf Model; 2009 Apr; 49(4):865-76. PubMed ID: 19323449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.
    Zhao Y; Aguilar A; Bernard D; Wang S
    J Med Chem; 2015 Feb; 58(3):1038-52. PubMed ID: 25396320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.